BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klein E, Hau AC, Oudin A, Golebiewska A, Niclou SP. Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy. Front Oncol 2020;10:604121. [PMID: 33364198 DOI: 10.3389/fonc.2020.604121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Garcia-Fabiani MB, Haase S, Comba A, Carney S, McClellan B, Banerjee K, Alghamri MS, Syed F, Kadiyala P, Nunez FJ, Candolfi M, Asad A, Gonzalez N, Aikins ME, Schwendeman A, Moon JJ, Lowenstein PR, Castro MG. Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies. Front Oncol 2021;11:631037. [PMID: 34168976 DOI: 10.3389/fonc.2021.631037] [Reference Citation Analysis]
2 Oudin A, Baus V, Barthelemy V, Fabian C, Klein E, Dieterle M, Wantz M, Hau AC, Dording C, Bernard A, Michelucci A, Yabo YA, Kanli G, Keunen O, Bjerkvig R, Niclou SP, Golebiewska A. Protocol for derivation of organoids and patient-derived orthotopic xenografts from glioma patient tumors. STAR Protoc 2021;2:100534. [PMID: 34027491 DOI: 10.1016/j.xpro.2021.100534] [Reference Citation Analysis]
3 Majc B, Novak M, Kopitar-Jerala N, Jewett A, Breznik B. Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development. Cells 2021;10:265. [PMID: 33572835 DOI: 10.3390/cells10020265] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
4 Prasad M, Kumar R, Buragohain L, Kumari A, Ghosh M. Organoid Technology: A Reliable Developmental Biology Tool for Organ-Specific Nanotoxicity Evaluation. Front Cell Dev Biol 2021;9:696668. [PMID: 34631696 DOI: 10.3389/fcell.2021.696668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jin F, Jin-lee HJ, Johnson AJ. Mouse Models of Experimental Glioblastoma. In: Debinski W, editor. Gliomas. Exon Publications; 2021. pp. 15-46. [DOI: 10.36255/exonpublications.gliomas.2021.chapter2] [Reference Citation Analysis]
6 Gatto L, Franceschi E, Di Nunno V, Maggio I, Lodi R, Brandes AA. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. Expert Rev Anticancer Ther 2021;21:1333-53. [PMID: 34734551 DOI: 10.1080/14737140.2021.1997599] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lange F, Hörnschemeyer J, Kirschstein T. Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy. Cells 2021;10:1226. [PMID: 34067762 DOI: 10.3390/cells10051226] [Reference Citation Analysis]
8 Deshmukh R, Allega MF, Tardito S. A map of the altered glioma metabolism. Trends Mol Med 2021;27:1045-59. [PMID: 34489164 DOI: 10.1016/j.molmed.2021.07.011] [Reference Citation Analysis]
9 Xu S, Yan X, Dai G, Luo C. A Novel Mice Model for Studying the Efficacy and IRAEs of Anti-CTLA4 Targeted Immunotherapy. Front Oncol 2021;11:692403. [PMID: 34178691 DOI: 10.3389/fonc.2021.692403] [Reference Citation Analysis]
10 Xu X, Li L, Luo L, Shu L, Si X, Chen Z, Xia W, Huang J, Liu Y, Shao A, Ke Y. Opportunities and challenges of glioma organoids. Cell Commun Signal 2021;19:102. [PMID: 34635112 DOI: 10.1186/s12964-021-00777-0] [Reference Citation Analysis]
11 Jurj A, Pasca S, Braicu C, Rusu I, Korban SS, Berindan-Neagoe I. Focus on organoids: cooperation and interconnection with extracellular vesicles - is this the future of in vitro modeling? Semin Cancer Biol 2021:S1044-579X(21)00295-9. [PMID: 34896267 DOI: 10.1016/j.semcancer.2021.12.002] [Reference Citation Analysis]
12 Stanković T, Ranđelović T, Dragoj M, Stojković Burić S, Fernández L, Ochoa I, Pérez-García VM, Pešić M. In vitro biomimetic models for glioblastoma-a promising tool for drug response studies. Drug Resist Updat 2021;55:100753. [PMID: 33667959 DOI: 10.1016/j.drup.2021.100753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Pfohl U, Pflaume A, Regenbrecht M, Finkler S, Graf Adelmann Q, Reinhard C, Regenbrecht CRA, Wedeken L. Precision Oncology Beyond Genomics: The Future Is Here-It Is Just Not Evenly Distributed. Cells 2021;10:928. [PMID: 33920536 DOI: 10.3390/cells10040928] [Reference Citation Analysis]
14 Youhanna S, Kemas AM, Preiss L, Zhou Y, Shen JX, Cakal SD, Paqualini FS, Goparaju SK, Shafagh RZ, Lind JU, Sellgren CM, Lauschke VM. Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development-Current State-of-the-Art and Future Perspectives. Pharmacol Rev 2022;74:141-206. [PMID: 35017176 DOI: 10.1124/pharmrev.120.000238] [Reference Citation Analysis]
15 Yabo YA, Niclou SP, Golebiewska A. Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma. Neuro Oncol 2021:noab269. [PMID: 34932099 DOI: 10.1093/neuonc/noab269] [Reference Citation Analysis]
16 Singh M, Dahal A, Brastianos PK. Preclinical Solid Tumor Models to Study Novel Therapeutics in Brain Metastases. Curr Protoc 2021;1:e284. [PMID: 34762346 DOI: 10.1002/cpz1.284] [Reference Citation Analysis]
17 Xie H, Appelt JW, Jenkins RW. Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology. Cancers (Basel) 2021;13:6052. [PMID: 34885161 DOI: 10.3390/cancers13236052] [Reference Citation Analysis]
18 Morimoto T, Nakazawa T, Matsuda R, Nishimura F, Nakamura M, Yamada S, Nakagawa I, Park YS, Tsujimura T, Nakase H. Evaluation of Comprehensive Gene Expression and NK Cell-Mediated Killing in Glioblastoma Cell Line-Derived Spheroids. Cancers (Basel) 2021;13:4896. [PMID: 34638384 DOI: 10.3390/cancers13194896] [Reference Citation Analysis]
19 Vargas-Toscano A, Janiak C, Sabel M, Kahlert UD. A Preclinical Pipeline for Translational Precision Medicine-Experiences from a Transdisciplinary Brain Tumor Stem Cell Project. J Pers Med 2021;11:892. [PMID: 34575669 DOI: 10.3390/jpm11090892] [Reference Citation Analysis]